News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

PDF

Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act)

Epigenomics AG issues new shares by way of private placement

Not for distribution in the United States of America

Berlin, Germany, May 24, 2016 – Epigenomics AG, Berlin, Germany (Frankfurt Prime Standard: ECX, ISIN: DE0000A11QW50), announces that the Company is raising around EUR 6.8 million of gross proceeds in a share capital increase.

The Executive Board of Epigenomics AG, with approval of the Supervisory Board, has today resolved on the increase of the Company’s share capital in the amount of EUR 1,436,000.00 by issuing 1,436,000 new registered shares of the Company from the Authorized Capital 2015/I against contribution in cash. The issue price has been set at EUR 4.76 per share, corresponding to the XETRA closing price on May 23, 2016.

The new shares will be issued by way of a private placement under exclusion of the shareholders’ preemptive rights and will be entitled to dividend rights as from the financial year beginning January 1, 2016.

About 55% of the capital increase will be acquired by the Company’s strategic partner BioChain, while the remaining shares issued under the capital increase will be acquired by institutional European investors.

Following the registration of the capital increase with the commercial register (“Handelsregister”), expected on or around June 3, 2016, the subscribed capital of Epigenomics AG will increase from currently EUR 19,108,009.00 to EUR 20,544,009.00. Subject to the registration of the implementation of the capital increase with the commercial register, the admission of the new shares to the regulated market (prime standard), of the Frankfurt Stock Exchange is expected on or around June 9, 2016. The technical implementation of the capital increase is conducted by Bankhaus Neelmeyer, Bremen, Germany.

Epigenomics AG intends to use the net proceeds from the offering to finance its current operations and to expand its U.S commercialization capacities for its lead product Epi proColon®, a blood-based test for the detection of colorectal cancer.

-End of Ad hoc-

Additional information:

Dr. Thomas Taapken commented: “We are pleased to announce the successful completion of a capital increase, leading to about EUR 6.8 million in proceeds for Epigenomics. With this investment we further strengthen our financial position, helping us in accelerating the implementation of our commercial strategy while gaining additional flexibility for exploring strategic options in the months to come. Furthermore, we are very pleased to further enhance an already strong relationship with our strategic partner BioChain and welcome the investment by them and a selected group of institutional investors from Europe.”

Disclaimer

This publication is not an offer of any securities for sale or a solicitation of an offer to purchase any securities.

This document is not an offer of securities for sale or a solicitation of an offer to purchase securities in the United States. The shares of Epigenomics AG (the “Shares”) have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an exemption from such registration. There will be no public offering of the Shares in the United States and the Shares will not be registered under the Securities Act.

Contact Epigenomics AG

Peter Vogt

Vice President Corporate Communications & Investor Relations

Epigenomics AG

Geneststraße 5

10829 Berlin

Phone +49 (0) 30 24345 386

ir@epigenomics.com

http://www.epigenomics.com